Association of Neutrophil to Lymphocyte Ratio With Plaque Rupture in Acute Coronary Syndrome Patients With Only Intermediate Coronary Artery Lesions Assessed by Optical Coherence Tomography

Jintong Jiang†, Huasu Zeng†, Yang Zhuo, Changqian Wang, Jun Gu, Junfeng Zhang* and Huili Zhang*

Department of Cardiology, Shanghai Ninth People’s Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China

Objectives: Plaque vulnerability and rupture rather than plaque size are the major cause of clinical events in patients with intermediate coronary lesions. Therefore, the present study was aimed to explore potential markers associated with plaque rupture in acute coronary syndrome (ACS) patients with intermediate coronary lesions.

Methods: A total of 82 ACS patients presenting with only intermediate coronary lesions (40–70% stenosis demonstrated by quantitative coronary angiography) and no severe stenosis in other main coronary arteries [median age 63 years, 53 male and 29 female] were enrolled. Plaque morphology were assessed by optical coherence tomography (OCT). Hematological indices were assayed by automated hematological analyzer.

Results: Plaque rupture was identified in 14 patients by OCT. Neutrophil to lymphocyte ratio (NLR) in patients with plaque rupture (n = 14) was significantly higher than that in patients with non-plaque rupture (n = 68) [3.85 (3.28, 4.77) vs. 2.13 (1.40, 2.81), p < 0.001]. Multivariate logistic regression analysis revealed that NLR was one of the independent risk factors for plaque rupture in intermediate coronary artery lesions (odds ratio 1.64, 95% confidence intervals 1.18–2.29, p = 0.003). ROC curve analysis found a cutoff point of NLR > 2.94 for plaque rupture with 93.8% sensitivity and 77.9% specificity.

Conclusion: NLR, an inflammatory biomarker, is closely associated with plaque rupture in intermediate coronary artery lesions. Monitoring NLR may be useful in risk stratification and management for intermediate coronary artery lesions.

Keywords: intermediate coronary artery lesion, plaque rupture, optical coherence tomography, neutrophil to lymphocyte ratio (NLR), atherosclerosis
INTRODUCTION

Intermediate coronary artery stenosis is defined as an angiographic stenosis of 40–70% (1, 2). It may account for up to 25% of patients undergoing coronary angiography (3). Optimal assessment and interventional strategy for intermediate lesions continues to be a clinical challenge for cardiologists. Therefore, it is meaningful to explore potential biomarkers which can provide useful information on pathophysiology, risk stratification and management for this condition.

Numerous studies have shown that plaque vulnerability and rupture rather than plaque size and stenosis severity are the major cause of cardiovascular events in patients with coronary artery disease (CAD) (4, 5). The process of plaque rupture may be attributed to neutrophil infiltration and subsequent neutrophil-platelet adhesion. Neutrophil infiltration in disrupted plaques and tissue damage caused by neutrophil elastase were directly visualized by immunohistochemistry in the arteries of the circle of Willis from human autopsy cases (6). Animal studies suggest that infiltrated neutrophils make plaques prone to rupture by releasing proteolytic enzymes, superoxide radicals and inflammatory mediators (7, 8).

Neutrophil to lymphocyte ratio (NLR), reflecting the combination of neutrophil and lymphocyte alterations is currently proposed as an accurate biomarker with predictive power for cardiovascular adverse events in patients with acute coronary syndrome (ACS), stable CAD patients and patients undergoing coronary artery bypass graft (CABG) (9–13). Unfortunately, to the best of our knowledge, there is a paucity of the association of NLR with plaque vulnerability in CAD patients, especially in patients with intermediate lesions. Given this background, the present study was aimed to investigate the possible link between NLR and plaque rupture in patients with only intermediate coronary lesions in the acute phase of ACS.

Optical coherence tomography (OCT) is a catheter-based imaging modality that provides detailed visualization of intraluminal coronary artery structures. By OCT imaging, cardiologists are able to observe the plaque morphology and intraluminal coronary artery structures. By OCT imaging, an imaging modality that provides detailed visualization of only intermediate coronary lesions in the acute phase of ACS.

All the patients received elective coronary angiography and OCT within 72 hours after admission. A total number of 82 ACS patients with only intermediate coronary lesions were finally enrolled and evaluated. One hundred and four ACS patients were excluded from the study because they also had severe stenosis (>70%) in other main coronary arteries. ACS was clinically diagnosed according to the elevated cardiac biomarkers, abnormal electrocardiogram indicating myocardial ischemia, clinical symptoms of angina pectoris or cardiac wall motion abnormalities by echocardiography. ACS included ST-segment elevation myocardial infarction (STEMI), non-ST-segment elevation myocardial infarction (NSTEMI), and unstable angina pectoris (UA). Patients with severe valvular heart disease, severe heart failure, infectious disease, autoimmune diseases, serious lung diseases, severe liver and kidney disease, malignant tumor, hemorrhage, and hematologic disorders were excluded from the study.

All patients were routinely treated with anti-platelet drugs, statins, β-blocker or angiotensin converting enzyme inhibitor or angiotensin II receptor blocker. Demographic information, clinical data and laboratory findings were collected. All the patients were followed up every 3 months for a median of 35.0 months [18.0, 45.5]. Major adverse cardiac events (MACE) were recorded during the period of follow-up. MACE was defined as the composite of all cause death, cardiac death, MI, coronary revascularization and stroke.

Coronary Angiography

All participants underwent elective coronary angiography by the standard Judkin’s technique. Coronary angiograms were assessed and quantified separately by two independent interventional physicians blind to the clinical data. An intermediate coronary lesion was defined as a luminal narrowing with a diameter stenosis of 40–70% in any of the main coronary arteries, including the left main artery (LM), left anterior descending artery (LAD), left circumflex coronary artery (LCX), and right coronary artery (RCA), or main branches of the vascular systems (the diameter of the target vessel is ≥ 2.5 mm).

Optical Coherence Tomography

Procedure and Imaging Analysis

All the intermediate lesions were assessed by OCT. OCT images were acquired using ILUMIEN OPTIS System with Dragonfly OPTIS imaging Catheter (Abbott Vascular, Santa Clara, CA, United States) and analyzed by two independent investigators who were blinded to the clinical presentations and angiographic findings. Morphological evaluation of intermediate lesions included plaque composition, plaque rupture, erosion, calcified nodule, vasospasm, and thrombus (14, 15). Plaque rupture was defined as the presence of a fibrous cap discontinuity and cavity formation in the plaque (Figure 1A).

Blood Examination

Blood samples for evaluating hematological parameters and biomarkers of cardiac injury and inflammation were collected from a large antecubital vein of each patient immediately after...
admission. Blood samples for assaying biochemical parameters were collected after a 12-h overnight fast usually within 24 hours after admission. Blood cell counts and hematological indices were determined using an automated blood cell counter, the Coulter LH780 Hematology Analyzer (Beckman Coulter Ireland Inc.). Serum levels of total cholesterol (TC), low-density lipoprotein cholesterol (LDL-C) and high-density lipoprotein cholesterol (HDL-C), and triglycerides (TG) were measured by biochemical auto-analyzer (Siemens Advia 2400). NLR was calculated by dividing neutrophil count to lymphocyte count. Platelet to lymphocyte ratio (PLR) was calculated by dividing platelet count to lymphocyte count.

**Statistical Analysis**

Statistical analysis was performed with SPSS version 21.0. Continuous variables were presented as median [first quartile, third quartile] and compared using the Mann-Whitney U test. Categorical variables were expressed as percentage and compared using the chi-square-test. Clinical features and hematological indices with p-value < 0.10 in univariate analysis were included in multivariate logistic regression analysis. Multivariate logistic regression analysis with forward stepwise was performed to evaluate the independent factors associated with the risk of plaque rupture. The odds ratios (OR) and 95% confidence intervals (CI) were calculated. Areas under the receiver-operator characteristic (ROC) curve for NLR related to plaque rupture were conducted. A two-tailed p-value of < 0.05 was considered statistically significant.

**RESULTS**

A total of 82 ACS patients (median age 63 years [57, 70], 53 male and 29 female) with only intermediate coronary lesion were enrolled and investigated. Sixty-six patients were diagnosed with UA. Fourteen and two patients were diagnosed with NSTEMI and STEMI, respectively. A total of 124 lesions (2 lesions in LM, 69 lesions in LAD, 18 lesions in LCX, and 35 lesions in RCA) were assessed by OCT. The OCT findings were described as follow: 35.7% (45/124) fibrous plaques, 22.6% (28/124) fibroatheroma, 8.1% (10/124) fibrocalcific plaques, 16.9% (21/124) mixed plaque, 11.3% (14/124) plaque rupture, 1.6% (2/124) spasm, 1.6% (2/124) dissection, 0.81% (1/124) intimal ulceration/erosion, and 0.81% (1/124) calcified nodule.
Patients were divided into rupture group (n = 14) and non-rupture group (n = 68) based on the OCT findings. Their demographic and clinical characteristics as well as laboratory data were summarized in Table 1. As shown in Table 1, patients in rupture group were significantly younger than non-rupture group. They also had higher proportions of male gender and current smokers as well as an increased level of Troponin I in comparison with non-rupture group. No substantial difference was observed between the two groups in terms of BNP, CRP, lipid profiles, hypertension, diabetes, and CAD family history. After follow-up for a median of 35 months [18.0, 45.5], an obvious difference was observed in the incidence of MACE between rupture and non-rupture group (3/14 vs. 3/68, \( p = 0.026 \)). Three patients (1 NSTEMI and 2 recurrent UA) in non-rupture group underwent revascularization because of exacerbation of stenosis severity in intermediate coronary lesions (>70% stenosis). In rupture group, one recurrent NSTEMI and one recurrent UA occurred. These two patients received drug-eluted stent implantation as the diameter stenosis caused by intermediate lesions dramatically increased to >70%. One patient in rupture group got ischemic stroke at 2-year follow-up.

Table 2 showed the comparison of hematological parameters between rupture and non-rupture groups. Total number of WBC and differential count of neutrophils in rupture group were significantly higher than those in non-rupture group (both \( p < 0.01 \)) whereas the lymphocyte count in rupture group was much lower than non-rupture group (\( p < 0.01 \)). Median NLR was 3.85 [3.28, 4.77] and 2.13 [1.40, 2.81] in rupture and non-rupture group, respectively. NLR in rupture group was significantly higher than that in non-rupture group (\( p < 0.001 \)). Median PLR was 169.45 [127.81, 210.21] and 121.62 [92.72, 160.04] in rupture and non-rupture groups, respectively and the difference between two groups was statistically significant (\( p = 0.002 \)). Additionally, the two groups had similar levels of red blood cell count, hemoglobin, mean corpuscular hemoglobin (MCH), mean corpuscular volume (MCV), red blood cell distribution width (RDW), monocyte count, platelet count, mean platelet volume (MPV), and platelet distribution width (PDW).

Logistic regression analysis was performed to identify potential risk factors of plaque rupture in ACS patients with only intermediate coronary lesions (Table 3). Multivariate logistic regression analysis showed that NLR (OR1.64, 95% CI 1.18–2.29, \( p = 0.003 \)) and status of current smoking (OR 6.74, 95% CI 1.61–28.21, \( p = 0.009 \)) were independent factors associated with the risk of plaque rupture in intermediate lesions. Moreover, ROC curve analysis identified that NLR of 2.94 was an optimal cutoff point of NLR for plaque rupture in ACS patients (95% sensitivity and 77.9% specificity) (AUC 0.882, CI 95% 0.809–0.955, \( p < 0.01 \)) for predicting plaque rupture (Figure 1B).

In addition, sex differences in inflammatory markers were obtained within rupture or non-rupture group.

**DISCUSSION**

Plaque rupture has been shown to be associated with the risk of MACE in patients with angiographically intermediate coronary artery lesions (16, 17). Exploring potential biomarkers associated with plaque rupture will be helpful in the follow-up of intermediate lesions and risk monitoring. NLR is a well-established and easily accessible inflammatory marker. Its prognostic value in CVD and predictive power for MACE have been highlighted by numerous epidemiological studies (9–13). Therefore, the present study assessed the plaque features in intermediate lesions by OCT and then explored the association of NLR with plaque rupture. We found that inflammation is more active in plaque rupture and elevated NLR is one of the independent risk factors for plaque rupture in intermediate lesions in the acute phase of ACS. The optimal cut-off point of NLR for plaque rupture in ACS patients with only intermediate lesions is \( > 2.94 \) with 93.8% sensitivity and 77.9% specificity. Our study suggests that NLR, an inexpensive and readily available marker may provide useful information on cardiovascular risk assessment and management in intermediate coronary lesions. To the best of our knowledge, it is first study to investigate the relationship between NLR and plaque rupture.

**TABLE 1 | Baseline demographic and clinical characteristics of patients with or without plaque rupture.**

| Age (years) | Plaque rupture (n = 14) | Non-plaque rupture (n = 68) | p-value |
|------------|------------------------|-----------------------------|---------|
| 57 [51, 65] | 64 [60, 70]             |                             | 0.005   |
| Male       | 12 (85.7%)             | 39 (57.4%)                  | 0.046   |
| Current smoking | 10 (71.2%) | 18 (26.5%)                  | 0.001   |
| Hypertension | 9 (64.3%) | 42 (61.7%)                  | 0.859   |
| Diabetes mellitus | 2 (14.3%) | 11 (16.2%)                  | 0.860   |
| Family history of CAD | 3 (21.4%) | 10 (14.7%)                  | 0.531   |
| Aspirin and/or thienopyridine | 12 (85.7%) | 60 (88.2%)                  | 0.793   |
| Beta blocker | 4 (28.6%) | 16 (23.5%)                  | 0.689   |
| ACEI/ARB | 6 (42.9%) | 26 (38.2%)                  | 0.859   |
| Statin | 8 (57.1%) | 35 (51.5%)                  | 0.699   |
| BMI (kg/m²) | 23.49 [21.34, 27.09] | 24.56 [23.25, 26.65] | 0.346   |
| TG (mmol/L) | 1.63 [0.97, 2.12] | 1.63 [1.18, 2.15] | 0.810   |
| TC (mmol/L) | 3.91 [3.47, 4.28] | 4.01 [3.52, 4.81] | 0.820   |
| LDL-C (mmol/L) | 2.73 [2.18, 3.21] | 2.70 [2.12, 3.47] | 0.844   |
| HDL-C (mmol/L) | 0.99 [0.84, 1.13] | 1.01 [0.90, 1.18] | 0.824   |
| Troponin I (mg/ml) | 0.07 [0.00, 0.71] | 0.01 [0.00, 0.03] | 0.003   |
| BNP (pg/ml) | 50.00 [25.75, 109.25] | 55.00 [25.00, 106.00] | 0.900   |
| CRP (mg/L) | 1.99 [1.28, 3.39] | 1.28 [1.28, 3.45] | 0.074   |
| eGFR (ml/min) | 79.54 [52.08, 99.28] | 64.30 [50.68, 78.40] | 0.068   |

Values are expressed as n (%) or median [first quartile, third quartile], CAD, coronary artery disease; ACEI, angiotensin converting enzyme inhibitor; ARB, angiotensin II receptor blocker; TC, total cholesterol; TG, triglyceride; LDL-C, low density lipoprotein cholesterol; HDL-C, high density lipoprotein cholesterol.
between increased neutrophils and acute cardiovascular events is significantly raised in plaque rupture group. The close correlation count was still within the normal range. As a results, NLR count in plaque rupture group although their total WBC in neutrophil count and a pronounced decrease in lymphocyte investigated the profiles of circulating leukocytes in patients role in every stage of atherosclerosis, the present study intermediate lesions.

As platelets contribute to the pathophysiology of ACS, the present study assessed the alterations of platelet indices (PLR, PDW, and MPV) in intermediate lesions. PLR dramatically increased in plaque rupture group while PDW and MPV remained unchanged. Unfortunately, PLR was not closely related to plaque rupture in intermediate lesions analyzed by multivariate analysis although it has been suggested to have a prognostic value in ACS patients because of the limited number of MACE observed during the follow-up. It warrants further investigation to elucidate whether NLR is a prognostic factor in patients with intermediate lesions.

As platelets contribute to the pathophysiology of ACS, the present study assessed the alterations of platelet indices (PLR, PDW, and MPV) in intermediate lesions. PLR dramatically increased in plaque rupture group while PDW and MPV remained unchanged. Unfortunately, PLR was not closely related to plaque rupture in intermediate lesions analyzed by multivariate analysis although it has been suggested to have a prognostic value in ACS patients (24, 25). On the other hand, it is worth emphasizing that EDTA, an anticoagulant used in blood sample collection may induce platelet swelling and thus it is worth emphasizing that EDTA, an anticoagulant used in blood sample collection may induce platelet swelling and thus the redistribution of lymphocytes to lymphoid organs and the inversion of CD4+/CD8+ T lymphocyte ratio (23).

Of note, NLR is a better marker of inflammation associated with plaque rupture than a single white blood cell count. Univariate logistic regression showed that neutrophil and lymphocyte differential counts as well as NLR were associated with plaque rupture. Nevertheless, by multiple logistic regression analysis, only NLR was identified as one of the independent factors associated with plaque rupture. Thus, NLR is likely to be a more accurate and reliable biomarker for evaluating inflammatory status and the risk of plaque rupture in intermediate lesions, as it reflects the combination of neutrophil and lymphocyte alterations in atherosclerotic events. In another word, ACS patients with only intermediate lesions should be cautiously monitored and followed-up when they have increased NLR > 2.94 (NLR cut-off value of 2.94 was observed in our study). Unfortunately, we did not analyze the predictive value of NLR to the long-term outcome of intermediate lesions in ACS patients because of the limited number of MACE observed during the follow-up. It warrants further investigation to elucidate whether NLR is a prognostic factor in patients with intermediate lesions.

1. **TABLE 2** Hematological indices of patients with or without plaque rupture.

|                         | Plaque rupture (n = 14) | Non-plaque rupture (n = 68) | p-value |
|-------------------------|-------------------------|-----------------------------|---------|
| Red blood cells (×10^{12}) | 4.54 [4.26, 4.80]       | 4.33 [3.99, 4.68]          | 0.590   |
| Hemoglobin (g/L)        | 140.50 [128.00, 146.75] | 134.00 [124.00, 141.00]    | 0.345   |
| MCH (pg)                | 30.40 [29.70, 31.58]    | 30.30 [29.22, 31.40]       | 0.426   |
| MCV (fL)                | 89.85 [88.53, 90.35]    | 90.10 [87.40, 92.70]       | 0.786   |
| RDW (%)                 | 13.10 [12.80, 13.50]    | 13.00 [12.40, 13.50]       | 0.286   |
| White blood cells (×10^{12}) | 7.50 [6.73, 8.15]       | 6.10 [5.10, 6.90]          | 0.006   |
| Neutrophils (×10^{9})   | 4.90 [4.00, 5.90]       | 3.50 [2.60, 4.40]          | 0.001   |
| Lymphocytes (×10^{9})   | 1.30 [1.10, 1.50]       | 1.70 [1.30, 2.00]          | 0.002   |
| Monocytes (×10^{9})     | 0.45 [0.39, 0.80]       | 0.44 [0.34, 0.60]          | 0.232   |
| Platelets (×10^{12})    | 228.00 [143.75, 262.00] | 206.00 [178.50, 224.75]    | 0.080   |
| MPV (fL)                | 10.05 [9.93, 10.88]     | 10.40 [9.90, 10.80]        | 0.887   |
| PDW (%)                 | 11.85 [10.60, 13.18]    | 12.30 [11.20, 13.20]       | 0.707   |
| PLR                     | 169.45 [127.81, 210.21] | 121.62 [92.72, 160.04]     | 0.002   |

Values are expressed as n (%) or median [first quartile, third quartile]; MCH, Mean corpuscular hemoglobin; MCV, Mean corpuscular volume; MPV, Mean platelet volume; NLR, Neutrophil to lymphocyte ratio; PLR, Platelet to lymphocyte ratio; PDW, Plate distribution width; RDW, Red blood cell distribution width.

2. **TABLE 3** Logistic regression analysis for plaque rupture in patients with intermediate coronary artery lesions.

|                         | Univariate | Multivariate |
|-------------------------|------------|-------------|
|                         | OR 95%CI   | p-value     | OR 95%CI   | p-value     |
| Age < 63 years*         | 3.62 [0.96–11.80] | 0.058       | 6.74 [1.61–28.21] | 0.009       |
| Male                    | 4.46 [0.93–21.49] | 0.062       |               |             |
| Current smoking         | 6.94 [1.93–24.94] | 0.001       | 6.74 [1.61–28.21] | 0.009       |
| Troponin I              | 1.95 [0.88–4.33] | 0.101       |               |             |
| WBC                     | 1.41 [1.03–1.94] | 0.031       |               |             |
| Neutrophils             | 1.65 [1.14–2.37] | 0.007       |               |             |
| Lymphocytes             | 0.10 [0.02–0.50] | 0.005       |               |             |
| NLR                     | 1.73 [1.21–2.46] | 0.002       | 1.64 [1.18–2.29] | 0.003       |
| PLR                     | 1.02 [1.00–1.03] | 0.002       |               |             |

*Age was categorized according to the median of age distribution (<63 years or ≥63 years).

and acute atherosclerotic events, for instance plaque rupture in intermediate lesions.

Since chronic inflammation in arterial walls plays an essential role in every stage of atherosclerosis, the present study investigated the profiles of circulating leukocytes in patients with only intermediate lesion. We found an obvious elevation in neutrophil count and a pronounced decrease in lymphocyte count in plaque rupture group although their total WBC count was still within the normal range. As a results, NLR significantly raised in plaque rupture group. The close correlation between increased neutrophils and acute cardiovascular events is well-established because the presence of neutrophil infiltration has been identified at the site of plaque rupture in both animal models and human autopsy cases (6–8). Moreover, lymphopenia is another common hematological finding observed in ACS or MI (18–20). Lymphopenia has recently been suggested to be associated with increased risk of long-term mortality in patients undergoing CAG, regardless of the coronary presentation (21). Several possible mechanisms may account for the reduction of circulating lymphocytes in acute cardiovascular events (22, 23). During the acute setting of coronary artery disease, activation of immune system increased lymphocyte apoptosis in atherosclerotic lesions, resulting in the destabilization of atherosclerotic plaques (22). In response to physiological stress, a release of cortisol, catecholamines, and proinflammatory cytokines may lead to lymphopenia (23). Acute stress also caused the redistribution of lymphocytes to lymphoid organs and the inversion of CD4+/CD8+ T lymphocyte ratio (23).

Of note, NLR is a better marker of inflammation associated with plaque rupture than a single white blood cell count. Univariate logistic regression showed that neutrophil and lymphocyte differential counts as well as NLR were associated with plaque rupture. Nevertheless, by multiple logistic regression analysis, only NLR was identified as one of the independent factors associated with plaque rupture. Thus, NLR is likely to be a more accurate and reliable biomarker for evaluating inflammatory status and the risk of plaque rupture in intermediate lesions, as it reflects the combination of neutrophil and lymphocyte alterations in atherosclerotic events. In another word, ACS patients with only intermediate lesions should be cautiously monitored and followed-up when they have increased NLR > 2.94 (NLR cut-off value of 2.94 was observed in our study). Unfortunately, we did not analyze the predictive value of NLR to the long-term outcome of intermediate lesions in ACS patients because of the limited number of MACE observed during the follow-up. It warrants further investigation to elucidate whether NLR is a prognostic factor in patients with intermediate lesions.

As platelets contribute to the pathophysiology of ACS, the present study assessed the alterations of platelet indices (PLR, PDW, and MPV) in intermediate lesions. PLR dramatically increased in plaque rupture group while PDW and MPV remained unchanged. Unfortunately, PLR was not closely related to plaque rupture in intermediate lesions analyzed by multivariate analysis although it has been suggested to have a prognostic value in ACS patients (24, 25). On the other hand, it is worth emphasizing that EDTA, an anticoagulant used in blood sample collection may induce platelet swelling and thus increasing the value of PDW and MPV (26). Some medications, such as statin also have effect on the variability in platelet size in CAD (27). Thus, the link between platelet indices and plaque rupture still warrants further investigation and these factors affecting platelet features should be taken into account in our future study. Additionally, other hematological parameters, such as monocyte count and RDW did not alter in plaque rupture group. Taken together, our findings show that platelet indices and RDW are not powerful indicators for plaque rupture in intermediate lesions.
In addition to NLR, we found that the status of current smoking is another attributor to the plaque rupture in intermediate lesions [OR 6.74, 95%CI 1.61–28.21]. It has been well-documented that cigarette smoke destabilizes plaques and promotes plaque rupture by enhancing inflammation, activating matrix metalloproteinases, stimulating platelet activation and shifting the balance of hemostasis toward thrombus formation (28, 29). Smoke quitting causes an exponential reduction in acute cardiovascular events, particularly in the first year after cessation (30). Therefore, smoke cessation is highly recommended in ACS patients although they have only intermediate coronary lesions, especially those whose NLR is more than 2.94.

Limitations of the Study
We recognized that there were several limitations in our study. Firstly, this prospective and observational study was conducted in a single center with a relatively small sample size. NLR was assayed in ACS patients with only intermediate lesions at admission. It is difficult to discriminate that NLR is upregulated before or after the event of plaque rupture. Thus, it is insufficient to provide a causative explanation for the association between NLR and plaque rupture in intermediate lesions. Secondly, it is difficult to analyze the prognostic value of NLR in intermediate coronary lesions because of the small sample size and the limited number of MACE. Thirdly, our findings may not reflect the alterations in female patients since the majority of the study population was male, especially in plaque rupture group. Large prospective cohort studies are required to obtain a better understanding between NLR and plaque rupture in intermediate lesions.

CONCLUSION
Increased NLR is associated with OCT identified-plaque rupture in ACS patients with only intermediate coronary artery lesions. NLR may be used as a potential biomarker for plaque rupture in risk stratification and management for intermediate coronary artery lesions.

REFERENCES
1. Tobis J, Azarbal B, Slavin L. Assessment of intermediate severity coronary lesions in the catheterization laboratory. J Am Coll Cardiol. (2007) 49:839–48. doi: 10.1016/j.jacc.2006.10.055
2. Levine GN, Bates ER, Blankenship JC, Bailey SR, Bittl JA, Cercek B, et al. 2011 ACCF/AHA/SCAI guideline for percutaneous coronary intervention: executive summary: a report of the American college of cardiology foundation/American heart association task force on practice guidelines and the society for cardiovascular angiography and interventions. Catheter Cardiovasc Interv. (2012) 79:453–95. doi: 10.1002/cdi.23438
3. Patel MR, Peterson ED, Dai D, Brennan JM, Redberg RF, Anderson HV, et al. Low diagnostic yield of elective coronary angiography. N Engl J Med. (2010) 362:886–95. doi: 10.1056/NEJMoa0907272
4. Burke AP, Farb A, Malcom GT, Liang YH, Smialek J, Virmani R, et al. Coronary risk factors and plaque morphology in men with coronary disease who died suddenly. N Engl J Med. (1997) 336:1276–82. doi: 10.1056/NEJM19970531361802
5. Kolodgie FD, Burke AP, Farb A, Gold HK, Yuan J, Narula J, et al. The thin-cap fibroatheroma: a type of vulnerable plaque: the major precursor lesion to acute coronary syndromes. Curr Opin Cardiol. (2001) 16:285–92. doi: 10.1097/00001573-200109000-00006
6. Larionov S, Dedeck O, Birkenmeier G, Thal DR. Expression of alpha2-macroglobulin, neutrophil elastase, and interleukin-1 alpha differs in early-stage and late-stage atherosclerotic lesions in the arteries of the circle of Willis. Acta Neuropathol. (2007) 113:33–43. doi: 10.1007/s00401-006-0134-0
7. Drexler M, Megens RT, van Zandvoort M, Weber C, Soehnlein O. Hyperlipidemia-triggered neutrophilia promotes early atherosclerosis. Circulation. (2010) 122:1837–45. doi: 10.1161/CIRCULATIONAHA.110.961714
8. Döring Y, Drexler M, Wanttha S, Kemmerich K, Lievens D, Vijayan S, et al. Lack of neutrophil-derived CRAMP reduces atherosclerosis in mice. Circ Res. (2012) 110:1052–6. doi: 10.1161/CIRCRESAHA.112.265868
9. Duffy BK, Gurm HS, Rajagopal V, Gupta R, Ellis SG, Bhatt DL. Usefulness of an elevated neutrophil to lymphocyte ratio in predicting long-term mortality
after percutaneous coronary intervention. *Am J Cardiol.* (2006) 97:993–6. doi: 10.1016/j.amjcard.2005.10.034
10. Gibson PH, Croal BL, Cuthbertson BH, Small GR, Ifezulike AI, Gibson G, et al. Preoperative neutrophil-lymphocyte ratio and outcome from coronary artery bypass grafting. *Am Heart J.* (2007) 154:995–1002. doi: 10.1016/ahj.2007.06.043
11. Dragu R, Huri S, Zukermann R, Suleiman M, Mutlak D, Agmon Y, et al. Predictive value of white blood cell subtypes for long-term outcome following myocardial infarction. *Atherosclerosis.* (2008) 196:405–12. doi: 10.1016/j.atherosclerosis.2006.11.022
12. Tamhane UU, Aneja S, Montgomery D, Rogers EK, Eagle KA, Gurm HS. Association between admission neutrophil to lymphocyte ratio and outcomes in patients with acute coronary syndrome. *Am J Cardiol.* (2008) 102:653–7. doi: 10.1016/j.amjcard.2008.05.006
13. Adlarstein NH, MacFadyen JG, Rose LM, Glynn RJ, Dey AK, Libby P, et al. The neutrophil-lymphocyte ratio and incident atherosclerotic events: analyses from five contemporary randomized trials. *Eur Heart J.* (2021) 42:896–903. doi: 10.1093/eurheartj/ehaa1034
14. Tearney GJ, Regar E, Akasaka T, Adriaenssens T, Barlis P, Bezerra HG, et al. Consensus standards for acquisition, measurement, and reporting of intravascular optical coherence tomography studies: a report from the international working group for intravascular optical coherence tomography standardization and validation. *J Am Coll Cardiol.* (2012) 59:1058–72. doi: 10.1016/j.jacc.2011.09.079
15. Mintz GS. Clinical utility of intravascular imaging and physiology in coronary artery disease. *J Am Coll Cardiol.* (2014) 64:207–22. doi: 10.1016/j.jacc.2014.01.015
16. Pijs NH, van Schaardenburgh P, Manoharan G, Boersma E, Bex JW, van’t Veer M, et al. Percutaneous coronary intervention of functionally nonsignificant stenosis: 5-year follow-up of the DEFER Study. *J Am Coll Cardiol.* (2007) 49:2105–11. doi: 10.1016/j.jacc.2007.01.087
17. Bae JH, Corban MT, Seo YH, Kim T, Lee G, Kwon TG, et al. Ten-year clinical outcomes of an intermediate coronary lesion: prognosis and predictors of major adverse cardiovascular events. *Int J Cardiol.* (2020) 299:26–30. doi: 10.1016/j.ijcard.2019.06.076
18. Núñez J, Núñez E, Bodí V, Sanchis J, Miñana G, Mainar L, et al. Usefulness of the neutrophil to lymphocyte ratio in predicting long-term mortality in ST segment elevation myocardial infarction. *Am J Cardiol.* (2008) 101:747–52. doi: 10.1016/j.amjcard.2007.11.004
19. Azab B, Zaher M, Weiserbs KF, Torbey E, Lacossiere K, Gaddam S, et al. Usefulness of neutrophil to lymphocyte ratio in predicting short- and long-term mortality after non-ST-elevation myocardial infarction. *Am J Cardiol.* (2010) 106:470–6. doi: 10.1016/j.amjcard.2010.03.062
20. Mor A, Luboshits G, Planer D, Keren G, George J. Altered status of CD4+CD25+ regulatory T cells in patients with acute coronary syndromes. *Eur Heart J.* (2006) 27:2530–7. doi: 10.1093/eurheartj/ehl222
21. Zafrir B, Hussein S, Jaffe R, Barnett-Griness O, Saliba W. Lymphopenia and mortality among patients undergoing coronary angiography: long-term follow-up study. *Cardiof.* (2020). doi: 10.5603/CJ.a2020.0141 [Epub ahead of print].
22. Pasqui AL, Di Renzo M, Bova G, Bruni F, Puccetti L, Pomppella G, et al. T cell activation and enhanced apoptosis in non-ST elevation myocardial infarction. *Clin Exp Med.* (2003) 3:37–44. doi: 10.1016/s1067-7845(02)00014
23. Hofmann U, Frantz S. Role of lymphocytes in myocardial injury, healing, and remodeling after myocardial infarction. *Circ Res.* (2015) 116:354–67. doi: 10.1161/CIRCRESAHA.116.304072
24. Azab B, Shah N, Akerman M, McGinn JT Jr. Value of platelet/lymphocyte ratio as a predictor of all-cause mortality after non-ST-elevation myocardial infarction. *J Thoroscl THBolysis.* (2012) 34:326–34. doi: 10.1016/s1213-012-0718-6
25. Wang Y, Peng Z. Prognostic value of platelet/lymphocyte ratio and CAMI-STEMI score for major adverse cardiac events in patients with acute ST segment elevation myocardial infarction after percutaneous coronary intervention: a prospective observational study. *Medicine (Baltimore).* (2021) 100:26942. doi: 10.1097/MD.00000000000026942
26. Thompson CR, Diaz DD, Quinn PG, Lapins M, Kurtz SR, Valeri CR. The role of antiaggregation in the measurement of platelet volumes. *Am J Clin Pathol.* (1983) 80:327–32. doi: 10.1093/ajcp/80.3.327
27. De Luca G, Venegoni L, Iorio S, Secco GG, Cassetti E, Verdia M, et al. Novara atherosclerosis study group. platelet distribution width and the extent of coronary artery disease: results from a large prospective study. *Platelets.* (2010) 21:508–14. doi: 10.3109/09537104.2010.494743
28. Cordas A, Bernhard D. The biology behind the atherothrombotic effects of cigarette smoke. *Nat Rev Cardiol.* (2013) 10:219–30. doi: 10.1038/nrcardio.2013.8
29. Messner B, Bernhard D. Smoking and cardiovascular disease: mechanisms of endothelial dysfunction and early atherogenesis. *Arterioscler Thromb Vasc Biol.* (2014) 34:509–15. doi: 10.1161/ATVBHA.113.300156
30. Critchley JA, Capewell S. Mortality risk reduction associated with smoking cessation in patients with coronary heart disease: a systematic review. *JAMA.* (2003) 290:86–97. doi: 10.1001/jama.290.1.86

**Conflict of Interest:** The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

**Publisher's Note:** All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Copyright © 2022 Jiang, Zeng, Zhou, Wang, Gu, Zhang and Zhang. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.